<DOC>
	<DOCNO>NCT00003124</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Hormone therapy use leuprolide flutamide may fight prostate cancer reduce production androgen . Combining radiation therapy hormone therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness hormone therapy plus radiation therapy treat patient prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy Plus Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess disease free survival patient localize adenocarcinoma prostate cancer . - Evaluate toxic effect three dimensional conformal external beam radiotherapy androgen deprivation patient . OUTLINE : Patients stratify accord PSA value Gleason score ( class II versus class III/IV ) . Patients receive intramuscular leuprolide acetate every 3 month , oral flutamide tid . Patients evaluate monthly basis response . Patients unchanged undetectable prostate specific antigen level consider reach maximal hormonal response three dimensional conformal external beam radiotherapy institute . In addition , patient disease progression consider reach maximal response , three dimensional conformal external beam radiotherapy institute . Radiotherapy must administer within 6 month initiation leuprolide flutamide therapy . Hormonal therapy administer 9 month treatment elapse . Patients follow every 3 month first year , every 4 month second third year , every 6 month thereafter . PROJECTED ACCRUAL : A total 105 patient accrue biologic class II 3 year , 58 patient biologic class III-IV .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven localized adenocarcinoma prostate Prostate specific antigen ( PSA ) great 4 Gleason score least 8 PSA great 4 CT , MRI , pelvic lymphadenectomy negative metastasis , PSA great 50 Negative pelvic lymphadenectomy , PSA great 50 Bone scan negative metastasis PSA great 20 PATIENT CHARACTERISTICS : Age : Not specify Performance Status : Not specify Life Expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 70,000/mm3 Hemoglobin least 10 g/dL Patients anticoagulant therapy must baseline PT test Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) ALT AST less 1.5 time ULN Alkaline phosphatase less 1.5 time ULN Renal : Creatinine le 1.5 time ULN Cardiovascular : No history collagen vascular disease Other : No acute infection require antibiotic No history hypersensitivity flutamide No history hypersensitivity leuprolide acetate PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>